| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/04/2007 | EP1768695A2 Amelioration of drug-induced toxicity |
| 04/04/2007 | EP1768688A2 Oral vaccine for borrelia |
| 04/04/2007 | EP1427405B1 Inflammation-inhibiting compounds |
| 04/04/2007 | EP1414858B1 Single chain camelid vhh antibodies, method for their production in a mammal, and their uses |
| 04/04/2007 | EP1352056B1 Polypeptides capable of eliciting an immune reaction against cancer |
| 04/04/2007 | EP1226256B1 Recombinant bifunctional fusion proteins for the clearance of variable viruses |
| 04/04/2007 | EP1137786B1 Virus coat protein/receptor chimeras and methods of use |
| 04/04/2007 | EP1105497B1 Cold-adapted equine influenza viruses |
| 04/04/2007 | EP0991756B1 Agents for the pre-symptomatic detection, prevention and treatment of breast cancer in humans |
| 04/04/2007 | EP0951292B1 Treating an ischemic disorder and improving stroke outcome |
| 04/04/2007 | CN1942767A Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose |
| 04/04/2007 | CN1942766A Method of evaluating the therapeutic potential of a vaccine for mucosal administration |
| 04/04/2007 | CN1942583A Optimized expression of HPV 58 L1 in yeast |
| 04/04/2007 | CN1942581A Antibody with osteoclast-related protein as target |
| 04/04/2007 | CN1942578A Low virulent strain of recombinant newcastle disease lasota vaccine expressing HA protein of avian influenza-H5 virus |
| 04/04/2007 | CN1942577A Method and kits for predicting infectious disease state |
| 04/04/2007 | CN1942483A Anti-P-selectin antibodies |
| 04/04/2007 | CN1942480A Identification of SNPs associated with hyperlipidemia, dyslipidemia and defective carbohydrate metabolism |
| 04/04/2007 | CN1942206A Pharmaceutical composition for treatment of immunological disorders |
| 04/04/2007 | CN1942205A Antigen-drug vehicle enabling transmucosal and transdermal administration and method of inducing mucosal immunity, mucosal vaccine and DDS using the same |
| 04/04/2007 | CN1942204A Inactivated mixed vaccine for porcine respiratory disease and the method of manufacturing thereof |
| 04/04/2007 | CN1942203A Screening method using antibody heavy chains |
| 04/04/2007 | CN1942202A Identification of self and non-self antigens implicated in autoimmune diseases |
| 04/04/2007 | CN1942201A Methods of modulating cytokine activity; related reagents |
| 04/04/2007 | CN1942199A Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes |
| 04/04/2007 | CN1942161A Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| 04/04/2007 | CN1940068A Novel receptor nucleic acids and polypeptides |
| 04/04/2007 | CN1940063A Pseudo-rabies gE/gI-gene loss poison strain, killed vaccine containing it and use |
| 04/04/2007 | CN1939931A Igy antibody and method for separating it from eggs of anseriformes selectively |
| 04/04/2007 | CN1939930A Low-molecular TPO agonist antibodies |
| 04/04/2007 | CN1939541A Immunostimulatory nucleic acids |
| 04/04/2007 | CN1939538A Use of osteopontin for the treatment and/or prevention of neurologic diseases |
| 04/04/2007 | CN1939537A Production of gamma immune protein capsules |
| 04/04/2007 | CN1939335A Cancer therapy using whole glucan particles and antibodies |
| 04/04/2007 | CN1308451C Tumor necrosis factor related ligand |
| 04/04/2007 | CN1308448C Degraded TPO agonist antibody |
| 04/04/2007 | CN1308447C Degraded agonist antibody |
| 04/04/2007 | CN1308347C Compositions and methods for cancer treatment by selectively inhibiting VEGF |
| 04/04/2007 | CN1308037C FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| 04/04/2007 | CN1308036C HPV polypeptide vaccine and its preparation method |
| 04/04/2007 | CA2570755A1 Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| 04/03/2007 | USRE39544 Viral obesity methods and compositions |
| 04/03/2007 | US7199234 Nucleotide sequences coding telomerase reverse transcriptase (TRT) for diagnosing and treating cancers; antiproliferative agents |
| 04/03/2007 | US7199231 Single-stranded polynucleotides that code for human melanoma antigen(MAGE) and human leukocyte antigens, used in gene therapy and medical diagnosis; immunology |
| 04/03/2007 | US7199229 Comprises serine protease for diagnosis, prognosis and treatment of cell proliferative disorders |
| 04/03/2007 | US7199216 Two covalently bonded peptide components, one component being an antigen associated with autoimmune disease, asthma, allergy or transplantation rejection, and the second being a T cell binding ligand modified to inhibit or suppress the activation of the class of T cells to which it selectively binds |
| 04/03/2007 | US7199162 Pretreatment before allogenic transplantation of bone marrow or haematopoietic stem cells; may be administered with other chemotherapeutic or immunosuppressive agents; antitumor and anticarcinogenic agents |
| 04/03/2007 | US7199152 TNF-α production inhibitor comprising kavalactone as an active ingredient |
| 04/03/2007 | US7199150 Amino alcohol compounds |
| 04/03/2007 | US7199108 Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines |
| 04/03/2007 | US7198934 Genetic engineering; gene insertion; culture product |
| 04/03/2007 | US7198913 Nucleotide sequences coding polypeptide for use in the treatment of apoptosis, inflammatory and autoimmune disorders |
| 04/03/2007 | US7198892 Hepatitis-C virus type 4, 5 and 6 |
| 04/03/2007 | US7198891 Hepatitis C virus peptides and uses thereof |
| 04/03/2007 | US7198793 Bovine immunodeficiency virus (BIV) based vectors |
| 04/03/2007 | US7198792 Alphaviral vector system comprising papilloma viral orgin of replication and antitumor agent for prevention and treatment urogenital cancer; gene therapy |
| 04/03/2007 | US7198791 Immunostimulants comprising epitopes from a malarial blood-stage protein |
| 04/03/2007 | US7198790 Growth differentiation factor-5 |
| 04/03/2007 | US7198789 Methods and compositions for modulating interleukin-21 receptor activity |
| 04/03/2007 | US7198788 Administering pharmaceutical formulation comprising an anti-CD26 antibody, whereby the anti- CD26 antibody binds CD26 and arrests cell cycle for therapy of cancer |
| 04/03/2007 | US7198787 Preferentially kill mammary gland cancer cells; obtain cells, exposed to mixture of toxins, monitor cellular response to toxins |
| 04/03/2007 | US7198783 Sensitization of neoplastic cells to radiation therapy with reovirus |
| 04/03/2007 | US7198774 Non-invasive localization of a light-emitting conjugate in a mammal |
| 04/03/2007 | CA2193365C Polynucleotide vaccine for papillomavirus |
| 04/03/2007 | CA2121559C Immunogenic artificial polypeptide |
| 04/03/2007 | CA2089661C Transgenic non-human animals capable of producing heterologous antibodies |
| 03/29/2007 | WO2007035897A2 Improved live attenuated vaccine strain for prevention of tularemia |
| 03/29/2007 | WO2007035872A2 Tdf-related compounds and analogs thereof |
| 03/29/2007 | WO2007035857A2 Treatment of b cell diseases using anti-germline antibody binding agents |
| 03/29/2007 | WO2007035842A2 Comprehensive diagnostic testing procedures for personalized anticancer chemotherapy (pac) |
| 03/29/2007 | WO2007035674A2 Vaccine for hair removal |
| 03/29/2007 | WO2007035624A1 Method for generating f(ab')2 antibody fragments |
| 03/29/2007 | WO2007035530A2 Ancestral dengue virus envelope protein sequence |
| 03/29/2007 | WO2007035406A1 Antibodies to complementary peptides of thrombin or portions thereof |
| 03/29/2007 | WO2007035368A2 Methods of screening for immuno-adjuvants and vaccines comprising anti-microtubule immuno-adjuvants |
| 03/29/2007 | WO2007034742A1 Method of treating virus-infected biological substance and cell, tissue and organ having been subjected to treatment against infecting virus |
| 03/29/2007 | WO2007034741A1 Anti-viral agent, and method for treatment of virus-infected cell |
| 03/29/2007 | WO2007034492A2 Fragrance dispensing device |
| 03/29/2007 | WO2007034489A2 Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom |
| 03/29/2007 | WO2007034219A2 Modifying leukocyte function |
| 03/29/2007 | WO2007034188A2 Chemo-immunotherapy method |
| 03/29/2007 | WO2007034166A2 Adjuvanted vaccine |
| 03/29/2007 | WO2007034022A1 Composition for administration to mammals or humans |
| 03/29/2007 | WO2007012811A3 Prostate stem cell markers |
| 03/29/2007 | WO2007012614A3 Novel anti-igf-ir antibodies and uses thereof |
| 03/29/2007 | WO2007010406A3 Obtention of food- or auto-antigen specific tr1 cells from a leukocyte or pbmc population |
| 03/29/2007 | WO2007009816A3 Plexin d1 as a target for tumor diagnosis and therapy |
| 03/29/2007 | WO2007008070A3 ADJUVATION THROUGH CROSS-β STRUCTURE |
| 03/29/2007 | WO2006138316A3 Methods for delivering molecules to the central nervous system |
| 03/29/2007 | WO2006130834A3 IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| 03/29/2007 | WO2006130356A3 Non-injection immunotherapy |
| 03/29/2007 | WO2006126030A3 Malaria vaccines |
| 03/29/2007 | WO2006125140A9 Methods for treating fibrotic conditions |
| 03/29/2007 | WO2006121664A3 Polypeptides for inducing a protective immune response against staphylococcus aureus |
| 03/29/2007 | WO2006110883A3 Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| 03/29/2007 | WO2006110881A3 Yersinia polypeptide vaccines, antibodies and immunomodulatory proteins |
| 03/29/2007 | WO2006110352A3 Separation of contaminants from streptococcus pneumoniae polysaccharide by ph manipulation |
| 03/29/2007 | WO2006107655A3 Use of wnv dna vaccine in combination with a conventional vaccine to overcome immunogen interference |
| 03/29/2007 | WO2006104890A3 Vaccines against chlamydial infection |
| 03/29/2007 | WO2006100679A3 Recombinant antibodies against human type ii transglutaminase and uses thereof |